The Know AML website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and Know AML cannot guarantee the accuracy of translated content. Know AML and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
How can we detect acute myeloid leukemia earlier?
Chris Hourigan
June 11, 2021
During the 2021 ASCO Annual Meeting, Know AML spoke with Chris Hourigan, National Institutes of Health, Bethesda, US. We asked, How can we detect acute myeloid leukemia earlier? Hourigan explains how to treat patients who initially respond to treatment (remission) but later have detectable leukemia again (relapse). He then explains how we can use better techniques to detect low amounts of disease in patients in remission, known as measurable residual disease (MRD). Finally, he explains the next stage of predicting patients at high risk of developing acute myeloid leukemia.
To what extent do you agree with the following statements?
Please rate between 1 and 5, with 1 being 'strongly disagree' and 5 being 'strongly agree'.
